FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING PSILOCYBIN FOR METHAMPHETAMINE USE DISORDER

The clinical trial will study PEX010, Filament’s botanical psilocybin drug candidate VANCOUVER, BC, March 15, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University of…

Source